All In Biotech

Drug Trial Radar · NCT04516915

IMU-838 and Oseltamivir in the Treatment of COVID-19

Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19

Last checked: Nov 19, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Jun 15, 2020

Primary completion

May 20, 2022

Study completion Sep 21, 2022

Sponsor

Lead sponsor
University Hospitals Coventry and Warwickshire NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Immunic AG; University of Warwick; MODEPHARMA
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects with coronavirus disease (COVID-19)

Conditions

  • Covid 19

Interventions

  • IMU-838Drug

    IMU-838 twice daily at 22.5mg doses for 14 days

  • OseltamivirDrug

    Oseltamivir twice daily at 75mg doses for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) vs. Oseltamivir alone in adult subjects with COVID-19Time frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Coventry and Warwickshire NHS Trust

    Coventry, West Midlands, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.